EP1890702A1 - Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires - Google Patents

Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires

Info

Publication number
EP1890702A1
EP1890702A1 EP06742947A EP06742947A EP1890702A1 EP 1890702 A1 EP1890702 A1 EP 1890702A1 EP 06742947 A EP06742947 A EP 06742947A EP 06742947 A EP06742947 A EP 06742947A EP 1890702 A1 EP1890702 A1 EP 1890702A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
mmol
preparation
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06742947A
Other languages
German (de)
English (en)
Inventor
Martin Hendrix
Frank Wunder
Adrian Tersteegen
Johannes-Peter Stasch
Martina Wuttke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1890702A1 publication Critical patent/EP1890702A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to the use of cynoopyrimidines for the preparation of medicaments for the treatment of cardiovascular diseases.
  • Inhibition of phosphodiesterases modulates levels of cyclic nucleotides 5'-3 'cyclic adenosine monophosphate (cAMP) and 5'-3' cyclic guanosine monophosphate (cGMP), respectively.
  • cAMP and cGMP cyclic nucleotides
  • cAMP and cGMP are important second messengers and therefore play a central role in the cellular signal transduction cascades. Both activate, inter alia, but not exclusively, again protein kinases.
  • the cAMP-activated protein kinase is called protein kinase A (PKA), and the cGMP-activated protein kinase is called protein kinase G (PKG).
  • PKA protein kinase A
  • PKG protein kinase G
  • Activated PKA or PKG can phosphorylate a variety of cellular effector proteins (e.g., ion channels, G protein-coupled receptors, structural proteins).
  • the second messengers cAMP and cGMP can control the most diverse physiological processes in various organs.
  • the cyclic nucleotides can also act directly on effector molecules.
  • cGMP can act directly on ion channels and thereby influence the cellular ion concentration (reviewed in: Wei et al., Prog. Neurobiol., 1998, 56: 37-64).
  • PDE phosphodiesterases
  • the human PDE9A was cloned and sequenced in 1998.
  • the amino acid identity to other PDEs is a maximum of 34% (PDE8A) and a minimum of 28% (PDE5A).
  • Km value Michaelis-Menten constant
  • PDE9A is highly affine for cGMP.
  • PDE9A has no cGMP binding domain suggestive of allosteric enzyme regulation by cGMP.
  • PDE9A has been shown to be expressed in human, inter alia, in the testes, brain, small intestine, skeletal muscle, heart, lungs, thymus and spleen. The highest expression has been found in brain, small intestine, heart and spleen (Fisher et al., J. Biol. Chem., 1998, 273 (25): 15559-15564).
  • the gene for human PDE9A is located on chromosome 21q22.3 and contains 21 exons.
  • 20 alternative splice variants of PDE9A have been identified (Guipponi et al., Hum.
  • Mouse PDE9A was described by Soderling et al. (J. Biol. Chem., 1998, 273 (25): 15553-15558) and sequenced. Like the human form, this is highly affine for cGMP with a Km of 70 nM. In the mouse, a particularly high expression in the kidney, brain, lung and heart was found. The mouse PDE9A is also not inhibited by IBMX in concentrations below 200 ⁇ M; the IC 50 value for zaprinast is 29 ⁇ M (Soderling et al., J. Biol. Chem., 1998, 273 (19): 15553-15558). In the rat brain, it has been shown that PDE9A is strongly expressed in some brain regions.
  • hippocampus hippocampus
  • cortex basal ganglia
  • basal forebrain Basal forebrain
  • US 5,002,949 discloses cyanopyrimidinones for the inhibition of white thrombus formations.
  • WO 02/06288 describes cyanopyrimidinones with mGluR antagonistic action.
  • cyanopyrimidinones are disclosed for the treatment of depression and Alzheimer's disease.
  • EP 130735 describes cyanopyrimidines as cardiotonic reagents.
  • the present invention relates to compounds of the formula
  • A is CpCg-alkyl, C 3 -Cg -cycloalkyl, tetrahydrofuryl or tetrahydropyranyl, which optionally with up to 3 radicals independently selected from the group
  • R 3 and R 4 are independently hydrogen or C 1 -C 6 -alkyl
  • R 3 and R 4 together with the nitrogen atom to which they are attached, denote 5- to 8-membered heterocyclyl
  • B is phenyl or heteroaryl optionally substituted with up to 3 groups each independently selected from the group Ci-C ⁇ alkyl, Ci-C ⁇ alkoxy, hydroxycarbonyl which
  • Ci-C ⁇ alkylaminocarbonyl C r C 6 alkoxycarbonyl, dC 6 alkylcarbonyl, CpC 6 - alkylsulfonyl, and Ci-C 6 substituted alkylthio,
  • R 3 and R 4 have the meanings given above,
  • a further embodiment of the invention relates to compounds of the formula (I)
  • Ci-C 5 alkyl or C 3 -C 6 cycloalkyl which is optionally substituted by up to 3 radicals independently selected from the group Ci-C4 alkyl, Ci-C4-alkoxy, hydroxycarbonyl, cyano, amino, hydroxy , 4 alkoxycarbonyl, C r C 6 alkylcarbonyl, Ci-C4-alkylsulfonyl and C r C 4 -alkylthio Ci-GrAlkylamino fluorine, chlorine, bromine, Ci-C,
  • C r C 4 -alkyl and CpC 4 -alkoxy optionally have a radical selected from the group consisting of hydroxyl, cyano, fluorine, chlorine, bromine, hydroxycarbonyl and a group of the formula -NR 3 R 4 ,
  • R 3 and R 4 independently of one another are hydrogen or C 1 -C 4 -alkyl
  • R 3 and R 4 together with the nitrogen atom to which they are attached, denote 5- to 6-membered heterocyclyl, are substituted
  • B is phenyl, thienyl or pyridyl, which are optionally each independently selected from the group consisting of C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, hydroxycarbonyl, with up to 3 radicals
  • C r C 4 alkyl and Ci-C 4 alkoxy optionally substituted with a radical selected from the group hydroxy, cyano, fluorine, chlorine, bromine, hydroxycarbonyl and a group of the formula -ISfR 3 R 4,
  • R 3 and R 4 have the meanings given above,
  • a further embodiment of the invention relates to compounds of the formula (I)
  • B is phenyl or pyridyl, which is optionally selected independently of one another from the group consisting of methyl, ethyl, 2-propyl, trifluoromethyl, methoxy, ethoxy, fluorine and chlorine, with up to 3 radicals,
  • a further embodiment of the invention relates to compounds of the formula (I)
  • a further embodiment of the invention relates to compounds of the formula (I)
  • A is 2-methylpropyl, 2-butyl, 2-pentyl or 3-pentyl and
  • a further embodiment of the invention relates to compounds of the formula (I)
  • B is phenyl, thienyl or pyridyl, which are optionally each independently selected from the group consisting of C 1 -C 3 -alkyl, trifluoromethyl, hydroxy, methoxy, with up to 3 radicals
  • Cycs alkyl. dVCfi-alkyl, CVCs-alkyl and CrCV-alkyl are a straight-chain or branched alkyl radical having 1 to 8, preferably 1 to 6, particularly preferably 1 to 5 and 1 to 4 carbon atoms.
  • Preferred examples include methyl, ethyl, n-propyl, isopropyl, 2-butyl, 2-pentyl and 3-pentyl.
  • for a straight-chain or branched alkoxy radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms.
  • Preferred examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • CVCfi-alkoxycarbonyl represents a straight-chain or branched alkoxycarbonyl radical having 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms.
  • Preferred examples include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.
  • C 1 -C 8 -alkylamino represents a straight-chain or branched mono- or dialkylamino radical having 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3, carbon atoms.
  • Preferred examples include methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino and n-hexylamino, dimethylamino, diethylamino, di-n-propylamino, diisopropylamino, di-tert-butylamino, di-n-pentylamino , Di-n-hexylamino, ethylmethylamino, isopropylmethylamino, n-butylethylamino and n-hexyl-i-pentylamino.
  • CVCV alkylaminocarbonyl is a mono- or dialkylamino radical linked via a carbonyl group, where the alkyl radicals may be identical or different, are straight-chain or branched and contain in each case 1 to 6, preferably 1 to 4, and particularly preferably 1 to 3, carbon atoms.
  • Preferred examples include methylaminocarbonyl, ethylaminocarbonyl, n -propylaminocarbonyl, isopropylaminocarbonyl, tert-butylaminocarbonyl, n -pentylaminocarbonyl, n-hexylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, di-n-propylaminocarbonyl, diisopropylaminocarbonyl, di-t-butylaminocarbonyl, di-n-pentylaminocarbonyl, di -n-hexylaminocarbonyl, ethylmethylaminocarbonyl, isopropylmethylaminocarbonyl, n-butylethylaminocarbonyl and n-hexyl-i-pentylaminocarbonyl. Furthermore, in the case of a dialkylamino radical, the two alky
  • dVCfi-alkylcarbonyl represents a straight-chain or branched alkylcarbonyl radical having 1 to 6 and preferably 1 to 4 carbon atoms. Examples which may be mentioned are: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, pentylcarbonyl and hexylcarbonyl. Particularly preferred are acetyl and ethylcarbonyl.
  • C r Cft-alkylsulfonyl is a straight-chain or branched alkylsulfonyl group having 1 to 6, preferably 1 to 4 and particularly preferably having 1 to 3 carbon atoms.
  • Preferred examples include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, t-butylsulfonyl, n-pentylsulfonyl and n-hexylsulfonyl.
  • C j -C f -alkylthio represents a straight-chain or branched alkylthio radical having 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms.
  • Preferred examples include methylthio, ethylthio, n-propylthio, isopropylthio, tert-butylthio, n-pentylthio and n-hexylthio.
  • Halogen is fluorine, chlorine, bromine and iodine. Preference is given to fluorine, chlorine, bromine, more preferably fluorine and chlorine.
  • Heteroaryl is an aromatic, monocyclic radical having 5 to 6 ring atoms and up to 3 heteroatoms from the series S, O and / or N. Preferred are 5- to 6-membered heteroaryls having up to 2 heteroatoms. The heteroaryl group may be bonded via a carbon or nitrogen atom. Preferred examples include thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, pyridyl, pyrimidinyl and pyridazinyl.
  • 3- to 8-membered cycloalkyl represents saturated and partially unsaturated non-aromatic cycloalkyl radicals having 3 to 8, preferably 3 to 6 and more preferably 5 to 6 carbon atoms in the cycle.
  • Preferred examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl.
  • 5- to 8-membered heterocyclyl is a mono- or polycyclic, heterocyclic radical having 5 to 8 ring atoms and up to 3, preferably 2 heteroatoms or hetero groups from the series N, O, S, SO, SO 2 .
  • Mono- or bicyclic heterocyclyl is preferred. Particularly preferred is monocyclic heterocyclyl.
  • heteroatoms N and O are preferred.
  • the heterocyclyl radicals may be saturated or partially unsaturated. Saturated heterocyclyl radicals are preferred. Particularly preferred are 5- to 7-membered heterocyclyl radicals.
  • Preferred examples include oxetan-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolinyl, tetrahydrofuranyl, tetrahydrothienyl, pyranyl, piperidinyl, thiopyranyl, morpholinyl, perhydroazepinyl.
  • radicals in the compounds according to the invention are optionally substituted, unless otherwise specified, a substitution with up to three identical or different substituents is preferred.
  • Another object of the present invention relates to compounds of the formula
  • D is phenyl, heteroaryl or a group of the formula
  • phenyl and heteroaryl where appropriate, having up to 2 radicals, independently of one another, are selected from the group consisting of heteroaryl, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl,
  • Ci-C ⁇ -alkyl optionally with a group of the formula -NR 5 R 6 , in which R 5 is C r C 6 alkyl and R 6 is hydrogen or C r C 6 alkoxy (Ci-C 6 ) - alkyl, and
  • Heteroaryl is optionally substituted by Ci-C ⁇ - alkoxy,
  • R 1 is C 3 -C 8 cycloalkyl, C r C 6 alkyl, C 1 -C 6 alkoxy (Ci-C 6) alkyl, benzyl or a group of
  • C 3 -C 8 -cycloalkyl is optionally substituted by hydroxy, CpC ⁇ -alkyl or trifluoromethyl
  • benzyl is optionally substituted by C 1 -C 6 -alkoxy or halogen
  • R 2 is hydrogen
  • R 1 and R 2 together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl, which is optionally selected from up to 2 substituents independently selected from the group CpC ⁇ -alkyl, hydroxy,
  • C 1 -C 6 -alkyl is optionally substituted by hydroxy or heteroaryl
  • Another embodiment of the invention relates to compounds of the formula (II) in which
  • phenyl and heteroaryl optionally with up to 2 radicals independently of one another are selected from the group heteroaryl, halogen, C 1 -C 4 -alkyl, CpC 4 -
  • Ci-Gj-alkyl optionally with a group of the formula -NR 3 R 4 , in which R 3 is C, -C 4 alkyl and R 4 is hydrogen or C r C 4 alkoxy (CpC 4 ) - alkyl, and
  • Heteroaryl is optionally substituted by C 1 -C 4 -alkoxy
  • R 1 is C 3 -C 6 cycloalkyl, C r C 4 alkyl, Ci-C 4 alkoxy (Ci-C 4) alkyl, benzyl or a group of
  • C 3 -C 6 -cycloalkyl is optionally substituted by hydroxyl, C 1 -C 4 -alkyl or trifluoromethyl,
  • benzyl is optionally substituted by C 1 -C 4 -alkoxy or halogen
  • R 2 is hydrogen
  • R 1 and R 2 together with the nitrogen atom to which they are attached, a 5- to 6-membered heterocyclyl, which is optionally substituted with up to 2 substituents independently selected from the group C r C 4 alkyl, hydroxy,
  • C r C 4 -alkyl is optionally substituted by hydroxy or heteroaryl
  • Another embodiment of the invention relates to compounds of the formula (II) in which A is phenyl, thienyl or a group of the formula
  • phenyl and thienyl are optionally substituted by up to 2 radicals independently of one another selected from the group of pyridyl, fluorine, chlorine, bromine, C 1 -C -alkyl, C 1 -C 4 -alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy and benzyl,
  • Ci-C 4 alkyl optionally having a group of the formula -NR 3 R 4 in which R 3 is C r C 4 alkyl and R 4 is hydrogen or C r C 4 alkoxy (C r C 4) - alkyl, and
  • Pyridyl is optionally substituted by C 1 -C 4 -alkoxy
  • R 1 is C 3 -C 6 cycloalkyl, C r C 4 alkyl, C r C 4 alkoxy (Ci-C 4) alkyl, benzyl or a group of
  • C 3 -C 6 -cycloalkyl is optionally substituted by hydroxy, C 1 -C 4 -alkyl or trifluoromethyl
  • benzyl is optionally substituted by C 1 -C 4 -alkoxy, fluorine, chlorine or bromine,
  • R 2 is hydrogen
  • R 1 and R 2 together with the nitrogen atom to which they are attached, a 5- to 6-membered heterocyclyl selected from the group pyrrolidinyl, piperidinyl,
  • C 1 -C 4 -alkyl is optionally substituted by hydroxy or pyridyl
  • Another embodiment of the invention relates to compounds of the formula (II) in which
  • A is phenyl, thienyl or a group of the formula
  • phenyl is optionally substituted by up to 2 independently selected from the group consisting of pyridyl, fluorine, chlorine, methyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, benzyloxy and benzyl,
  • methyl is optionally substituted by a group of the formula -NR 3 R 4 , in which R 3 is methyl and R 4 is hydrogen or 2-methoxyethyl, and
  • Pyridyl is optionally substituted with methoxy
  • R 1 is C 3 -C 6 -cycloalkyl, methyl, ethyl, propyl, 2-methoxyethyl, benzyl or a group of
  • C 3 -C 6 -cycloalkyl is optionally substituted by hydroxy, methyl or trifluoromethyl
  • R 2 is hydrogen
  • R 1 and R 2 together with the nitrogen atom to which they are attached, a 5- to 6-membered heterocyclyl selected from the group pyrrolidinyl, piperidinyl,
  • Piperazinyl and morpholinyl which are optionally selected with up to 2 substituents independently selected from the group of methyl, ethyl, propyl, tert-butyl, hydroxy, cyano, oxo, pyridyl, benzyl, formyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl and a the following groups
  • OrCfi-alkyl is a straight-chain or branched alkyl radical having 1 to 6, preferably 1 to 4 carbon atoms. Preferred examples include methyl, ethyl, n-propyl, isopropyl, 2-butyl, tert-butyl, 2-pentyl, 3-pentyl and n-hexyl.
  • C 1 -Cs-AIkOXV represents a straight-chain or branched alkoxy radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms.
  • Preferred examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Preferred examples include methoxymethyl, 2-methoxyethyl, ethoxymethyl and 2-ethoxyethyl.
  • C j -CFT-Alkylcarbonyl is a straight-chain or branched alkylcarbonyl group having 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms.
  • Preferred examples include methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl and tert-butylcarbonyl.
  • 3- to 8-membered cycloalkyl represents saturated cycloalkyl radicals having 3 to 8, preferably 3 to 6 and more preferably 5 to 6 carbon atoms in the cycle.
  • Preferred examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Halogen is fluorine, chlorine, bromine and iodine. Preference is given to fluorine, chlorine, bromine, more preferably fluorine and chlorine.
  • Heteroaryl is an aromatic, monocyclic radical having 5 to 6 ring atoms and up to 3 heteroatoms from the series S, O and / or N. Preferred are 5- to 6-membered heteroaryls having up to 2 heteroatoms. The heteroaryl group may be bonded via a carbon or nitrogen atom. Preferred examples include thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidinyl and pyridazinyl.
  • 5- to 6-membered heterocyclyl is a monocyclic, saturated or partially unsaturated heterocyclic radical having 5 to 6 ring atoms and up to 2 heteroatoms from the series N, O, S.
  • heteroatoms N and O are preferred.
  • Preferred examples include pyrrolidinyl, pyrrolinyl, tetrahydrofuranyl, tetrahydrothienyl, pyranyl, thiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl.
  • radicals in the compounds of the invention are optionally substituted, unless otherwise specified, substitution with up to three identical or different substituents is preferred.
  • R 1 and R 2 have the meanings given above,
  • R 1 and R 2 have the meanings given above,
  • the compound of the formula (III) is known from the literature (R. Gompper, W. Toepfl, Chem. Ber. 1962, 95, 2861-2870).
  • the compounds of the formulas (IV) and (VI) are commercially available, known from the literature or can be prepared in analogy to processes known from the literature (see, for example, H. Gielen, C. Alonso-Alija, M. Hendrix, U. Nie Strukturer, D. Schauß, Tetrahedron Lett., 2002, 43, 419-421).
  • high-boiling, inert organic solvents are suitable which do not change under the reaction conditions. These include preferably toluene, acetonitrile, dimethylformamide, dimethyl sulfoxide or sulfolane. It is likewise possible to carry out the reaction without solvent in the melt. Particularly preferred is a reaction without solvent or in dimethylformamide, acetonitrile or toluene.
  • the reaction is generally carried out in a temperature range from + 70 ° C to +200 0 C, preferably in a temperature range from +100 0 C to + 15O 0 C.
  • the reaction may be at atmospheric, ER- be performed elevated or at reduced pressure (eg from 0.5 to 5 bar). Generally, one works at normal pressure.
  • the compound of the formula (IV) is used here in an amount of 1 to 2 mol, preferably in an equivalent amount of 1 mol, based on 1 mol of the compound of the formula (HI).
  • organic solvents which do not change under the reaction conditions. These preferably include dimethylformamide, dimethylsulfoxide or acetonitrile. It is also possible to carry out the reaction without solvent. Particularly preferred is a reaction without solvent or in acetonitrile.
  • the reaction is generally carried out in a temperature range from + 5O 0 C to +150 0 C, preferably installed into a temperature range of + 7O 0 C to +100 0 C.
  • the reaction can be carried out at atmospheric, elevated or reduced pressure (eg from 0.5 to 5 bar). Generally, one works at normal pressure.
  • the compound of the formula (TV) is in this case used in an amount of 1 to 10 mol, preferably in an excess of 3 to 10 mol, based on 1 mol of the compound of the formula (VII).
  • ком ⁇ онентs which do not change under the reaction conditions. These include preferably dimethylformamide, dimethyl sulfoxide, acetonitrile, dioxane or alcohols such as methanol, ethanol, propanol, isopropanol, n-butanol or tert-butanol. It is also possible to use mixtures of said solvents. Particularly preferred for the process step (V) + (VI) -> (II) dimethylformamide or acetonitrile and for the process step (DI) + (VI) -> (VIT) ethanol.
  • the reaction is generally carried out in a temperature range of +50 0 C to +150 0 C, preferably in a temperature range of +70 0 C to +100 0 C.
  • the reaction can be carried out at normal, elevated or at reduced pressure (eg 0.5 to 5 bar). Generally, one works at normal pressure.
  • Suitable bases for process step (V) + (VI) ⁇ (E) or (HI) + (VI) ⁇ (VE) are preferably alkali metal carbonates such as lithium, sodium, potassium or cesium carbonate or organic amine bases such as for example, pyridine, triethylamine, ethyldiisopropylamine, N-methylmorpholine or N-methylpiperidine. Particularly preferred is potassium carbonate or triethylamine.
  • the base is used here in an amount of 1.5 to 4 mol, preferably in an amount of 1.5 to 2 mol, based on 1 mol of the compound of the formula (V) or (BT).
  • the connection of Formula (VI) is used in an amount of 1 to 1.5 mol, preferably in an amount of 1.2 mol, based on 1 mol of the compound of formula (V) or (III).
  • Compounds of the invention are the compounds of formula (I) and (II) and their salts, solvates and solvates of the salts; the compounds of formulas (I) and (II) of the following formulas and their salts, solvates and solvates of the salts and of formulas (I) and (II), hereinafter referred to as exemplary compounds and their salts, solvates and solvates the salts, as far as the compounds encompassed by formulas (I) and (II), are not already salts, solvates and solvates of the salts.
  • the compounds of the invention may exist in stereoisomeric forms (enantiomers, diastereomers).
  • the invention therefore relates to the enantiomers or diastereomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner.
  • Physiologically acceptable salts of the compounds of formulas (I) and (II) include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid acetic acid, propionic acid, lactic acid, tartaric
  • Physiologically acceptable salts of the compounds of formulas (I) and (II) also include salts of conventional bases such as, for example, and preferably alkali metal salts (eg, sodium and potassium salts), alkaline earth salts (eg, calcium and magnesium salts), and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, dehydroabietylamine, arginine, lysine, ethylenediamine and methylpiperidine.
  • alkali metal salts eg, sodium and potassium salts
  • alkaline earth salts eg, calcium and magnesium salts
  • solvates are those forms of the compounds which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water.
  • the present invention also includes prodrugs of the compounds of the invention.
  • prodrugs includes compounds which may themselves be biologically active or inactive, but which are converted during their residence time in the body into compounds of the invention (for example metabolically or hydrolytically).
  • the compounds of the invention show an unpredictable, valuable pharmacological and pharmacokinetic activity spectrum. They are characterized in particular by an inhibition of PDE9A.
  • the compounds according to the invention are suitable for the preparation of medicaments for the treatment of cardiovascular diseases.
  • the compounds according to the invention can be used alone or in combination with other medicaments for the treatment of cardiovascular diseases.
  • cardiovascular diseases such as hypertension and cardiac insufficiency, acute heart failure, stable and unstable angina pectoris, peripheral and cardiovascular diseases, arrhythmias, for the treatment of thromboembolic disorders and ischaemias such as myocardial infarction, stroke, transient and ischemic attacks, peripheral circulatory disorders, prevention of restenosis such as after thrombolytic therapy, percutaneous transluminal angioplasties (PTA), percutaneous transluminal coronary angioplasty (PTCA), bypass and for the treatment of arteriosclerosis, asthmatic diseases and diseases of the genitourinary system such as prostatic hypertrophy, erectile dysfunction, female sexual Dysfunction, osteoporosis, glaucoma, pulmonary hypertension, portal hypertension, ischemic kidney disease, nephrosis, such as the nephrotic syndrome, renal stenosis, kidney insufficiency, acute renal failure, metabolic syndrome, gastroparesis, incontinence, liver
  • cardiovascular diseases such as hypertension and cardiac in
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2795
  • Eluent A 1 l of water + 0.5 ml of 50% formic acid
  • eluent B 1 l of acetonitrile + 0.5 ml of 50% formic acid
  • Gradient: 0.0 min 90% A flow 1 ml / min ⁇ 2.5 min 30% A, flow 2 ml / min ⁇ 3.0 min 5% A, flow 2 ml / min - »4.5 min 5% A, flow 2 ml / min ; Oven: 5O 0 C
  • UV detection 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC HP 1100 Series
  • UV DAD Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm
  • Eluent A 1 l of water + 0.5 ml of 50% formic acid
  • eluent B 1 l of acetonitrile + 0.5 ml of 50% formic acid
  • Gradient: 0.0 min 90% A flow 1 ml / min ⁇ 2.5 min 30% A, flow 2 ml / min ⁇ 3.0 min 5% A, flow 2 ml / min ⁇ 4.5 min 5% A, flow 2 ml / min
  • Oven 50 ° C .
  • UV detection 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC HP 1100 Series
  • UV DAD Column: Grom-Sil 120 ODS-4 HE 50 mm ⁇ 2 mm, 3.0 ⁇ m
  • Eluent A water + 500 ⁇ l 50% formic acid / 1
  • eluent B acetonitrile + 500 ⁇ l 50% formic acid / 1
  • Oven 50 ° C .
  • Flow 0.8 ml / min
  • UV detection 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2790
  • Eluent A water + 500 ⁇ l 50% formic acid / 1
  • eluent B acetonitrile + 500 ⁇ l 50% formic acid / 1
  • Oven 45 ° C .
  • UV detection 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2790
  • Eluent A water + 500 ⁇ l 50% formic acid / 1
  • eluent B acetonitrile + 500 ⁇ l 50% formic acid / 1
  • Oven 45 ° C .
  • UV detection 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2795; Column: Merck Chromolith SpeedROD RP-18e 50 mm x 4.6 mm; Eluent A: water + 500 ⁇ l 50% formic acid / 1, eluent B: acetonitrile + 500 ⁇ l 50% formic acid / 1; Gradient: 0.0 min 10% B ⁇ 3.0 min 95% B ⁇ 4.0 min 95% B; Oven: 35 ° C; Flow: 0.0 min 1.0 ml / min ⁇ 3.0 min 3.0 ml / min ⁇ 4.0 min 3.0 ml / min; UV detection: 210 nm.
  • Device type MS Micromass ZQ
  • Device type HPLC Waters Alliance 2790; Column: Uptisphere C 18 50 mm x 2.0 mm, 3.0 ⁇ m; Eluent B: acetonitrile + 0.05% formic acid, eluent A: water + 0.05% formic acid; Gradient: 0.0 min 5% B ⁇ 2.0 min 40% B ⁇ 4.5 min 90% B ⁇ 5.5 min 90% B; Oven: 45 ° C; Flow: 0.0 min 0.75 ml / min ⁇ 4.5 min 0.75 ml / min ⁇ 5.5 min 1.25 ml / min; UV detection: 210 nm.
  • amidines required for the following reactions are prepared from the corresponding nitriles or esters according to Gielen H., Alonso-Aliaja C, Hendrix M., Nieelleer U., Schauß D., Tetrahedron Lett. 43, 419-421 (2002).
  • the product is separated from the precipitated solid by suction and the filter cake washed several times with methanol.
  • the combined filtrates are concentrated to dryness, the residue is then slurried in dichloromethane / methanol 10: 1 and again filtered off with suction. After concentration, the filtrate gives 0.5 g (46% of theory) of the title compound.
  • Example 2A Analogously to the preparation of Example 2A, 0.5 g (2.00 mmol) of 2- (3-chlorophenyl) ethanamidine hydrobromide with 0.41 g (2.00 mmol) of methyl 2-cyano-3,3-dimethylthioprop-2-enoate and 0.81 g (8.01 mmol ) Reacted triethylamine to 0.5 g (86% of theory) of the title compound.
  • Example 2A Analogously to the preparation of Example 2A, 1.00 g (4.17 mmol) of 2- (3,4-dichlorophenyl) ethanediamine hydrochloride with 0.85 g (4.17 mmol) of methyl 2-cyano-3,3-dimethylthioprop-2-enoate and 1.69 g (16.7 mmol) of triethylamine to 0.6 g (44% of theory) of the title compound.
  • Example 2A Analogously to the preparation of Example 2A, 100 mg (0.43 mmol) of 2- (3-fluorophenyl) ethanediamine hydrochloride are reacted with 87 mg (0.43 mmol) of methyl 2-cyano-3,3-dimethylthioprop-2-enoate and 174 mg ( 1.72 mmol) of triethylamine were reacted to give 28 mg (24% of theory) of the title compound. - -
  • Example 2A Analogously to the preparation of Example 2A, 0.5 g (2.10 mmol) of 2- [3- (trifluoromethyl) phenyl] ethanamidine hydrochloride with 0.43 g (2.10 mmol) of methyl 2-cyano-3,3-dimethylthioprop-2-enoate and 0.85 g (8.38 mmol) of triethylamine to 0.4 g (59% of th.) Of the title compound.
  • PDE1C Recombinant PDE1C (GenBank / EMBL Accession Number: NM_005020, Loughney et al., J. Biol. Chem., 1996 271, 796-806), PDE2A (GenBank / EMBL Accession Number: NM_002599, Rosman et al., Gene 1997, 191, 89-95 ), PDE3B (GenBank / EMBL Accession Number: NM_000922, Miki et al, Genomics 1996, 36, 476-485), PDE4B (GenBank / EMBL Accession Number: NM_002600, Obernolte et al., Gene., 1993, 129, 239-247).
  • PDE5A GenBank / EMBL Accession Number: NM 001083, Loughney et al, Gene 1998, 216, 139-147
  • PDE7B GenBank / EMBL Accession Number: NM_018945, Hetman et al. Proc. Natl. Acad. Be. USA 2000, 97, 472-476
  • PDE8A GenBank / EMBL Accession Number: AF_056490, Fisher et al., Biochem Biophys Res. Commun. 1998 246, 570-577
  • PDE9A Fisher et al., J.
  • test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A.
  • serial dilutions 200 ⁇ M to 1.6 ⁇ M are prepared (resulting final concentrations in the assay: 4 ⁇ M to 0.032 ⁇ M).
  • 2 ⁇ L each of the diluted substance solutions are placed in the wells of microtiter plates (Isoplate, Wallac Inc., Atlanta, GA). Subsequently, 50 ⁇ L of a dilution of the PDE9A preparation described above is added.
  • the dilution of the PDE9A preparation is chosen such that during the later incubation less than 70% of the substrate is reacted (typical dilution: 1: 10,000; dilution buffer: 50 mM Tris / HCl pH 7.5, 8.3 mM MgCl 2 , 1.7 mM EDTA, 0.2% BSA).
  • the substrate, [8- 3 H] guanosine 3 ', 5 ( cyclic phosphate (1 ⁇ Ci / ⁇ L; Ameram Pharmacia Biotech., Piscataway, NJ) is diluted 1: 2000 with assay buffer (50 mM Tris / HCl pH 7.5, 8.3 mM MgCl 2 , 1.7 mM EDTA) to a concentration of 0.0005 ⁇ Ci / ⁇ L
  • 50 ⁇ L (0.025 ⁇ Ci) of the diluted substrate the enzyme reaction is finally started
  • the test mixtures are incubated for 60 min at room temperature and the reaction by 25 ⁇ l of a suspension containing 18 mg / ml of Yttrium Scintillation Proximity Beads (Amersham Pharmacia Biotech., Piscataway, Biol.) Are then added, followed by 25 ⁇ l of a PDE9A inhibitor dissolved in assay buffer (eg the inhibitor from Preparation Example 1, 10
  • microtiter plates are sealed with a foil and allowed to stand at room temperature for 60 min, then the plates are measured for 30 s per well in a microbeta scintillation counter (Wallac Inc., Atlanta, GA) IC 5 o values are determined by plotting the concentration of the substance against the percent inhibition.
  • PDE10A and PDEI IA are determined according to the assay protocol described above for PDE 9A with the following adaptations:
  • the substrate used is [5 ', 8- 3 H] adenosine 3', 5'-cyclic phosphate (1 - 7 - ⁇ Ci / ⁇ L; Amersham Pharmacia Biotech., Piscataway, NJ).
  • the addition of an inhibitor solution to stop the reaction is not necessary. Instead, following the incubation of substrate and PDE, the addition of the Yttrium Scintillation Proximity Beads is continued as described above, thereby stopping the reaction.
  • PDE2A PDE5 and the protocol is additionally adapted as follows: In pdel Calmodulin 10 -7 M and CaCl 2 are added 3 mM to the reaction mixture in addition. PDE2A is stimulated in the assay by addition of cGMP 1 ⁇ M and tested with a BSA concentration of 0.01%.
  • the force of contraction is detected with Statham UC2 cells, amplified and digitized via A / D converters (DAS-1802 HC, Keithley Instruments Munich) and registered in parallel on chart recorders.
  • DAS-1802 HC A / D converters
  • phenylephrine is added cumulatively to the bath in increasing concentration.
  • the substance to be examined is examined in each subsequent passage in increasing dosages and the height of the contraction is compared with the height of the contraction achieved in the last predistortion. This is used to calculate the concentration required to reduce the level of the control value by 50% (IC 50 ).
  • the standard application volume is 5 ⁇ l, the DMSO content in the bath solution corresponds to 0.1%.
  • test substances are dissolved in a mixture of glycerol: water: polyethylene glycol 6: 10: 9.69 and applied in a volume of 1 ml / kg with the gavage.
  • mice Male Wistar rats weighing 300-350 g (Harlan Winkelmann, Germany) were anesthetized with 1-2.5% isofluoran in a mixture of nitrous oxide / O 2 (2: 1).
  • a catheter was inserted into the femoral artery, the substance was administered via a femoral vein catheter and urine collection via a bladder catheter. After the operation, 5 ml / kg of phys. NaCl were given intravenously as a bolus to equalize the fluid and the animals were infused continuously for 1 h with phys. NaCl at a rate of 100 ⁇ l / kg / min via the venous catheter. The body temperature of the animals was kept constant over a hot plate.
  • test substances along with ANP were continuously infused via the venous catheter at a rate of 100 ⁇ l / kg / min.
  • Urine was collected every 15 min and the volume, cGMP content (RIA), and Na + and K + concentrations (flame photometry) were measured.
  • the substance to be tested is administered intravenously to animals (for example mouse, rat, dog) as a solution, and the oral administration is carried out as a solution or suspension via a gavage.
  • animals for example mouse, rat, dog
  • the animals are bled at fixed times, this is heparinized and then plasma is recovered therefrom by centrifugation.
  • the substance is analytically quantified in the plasma via LC / MSMS.
  • the pharmacokinetic parameters are calculated from the plasma concentration / time profiles determined in this way by means of a validated pharmacokinetic calculation program.
  • Recombinant enzymes eg CYP 1A2, 2C8, 2C9, 2CI9, 2D6 or 3A4
  • substrates generally containing fluorescein or coumarin substructures are used in the assay for the formation of fluorescent metabolites.
  • a substrate concentration and 8 concentrations of the potential inhibitor are used.
  • the extent of fluorescent metabolites in comparison to the control (without inhibitor) is determined by means of fluorescence readers and an IC 50 value is calculated [Anal. Biochem. 248, 188 (1997)].
  • the second assay uses human liver microsomes as the enzyme source and phenacetin (CYP1A2), diclofenac (CYP2C9), dextromethorphan (CYP2D6) and CYP isoform-selective substrates Midazolam (CYP3A4) used.
  • CYP1A2 phenacetin
  • CYP2C9 diclofenac
  • CYP2D6 dextromethorphan
  • CYP3A4 CYP isoform-selective substrates Midazolam
  • K 1 values are calculated from the reduction in metabolite formation compared to the control (1 substrate, 3 inhibitor concentrations).
  • the hepatocytes are treated for 5 days in duplicate with different concentrations of the test substances compared with the inducers rifampicin (RIF, 50 ⁇ M), omeprazole (OME, 100 ⁇ M) and phenobarbital (PB, 2 mM).
  • the final concentrations of the test substances are 0.01-10 ⁇ g / ml.
  • the cell cultures show the inductive effect of the test substances on the cytochrome (CYP) P450 enzymes 1A2, 2B6, 2C19 and 3A4 by adding the substrates 7-ethoxyresorufin (CYP1A2), [ 14 C] -S-mephenytoin (CYP2B6 and 2Cl 9) and [ 14 C] -testosterone (CYP3A4) at day 8. From the thus measured enzyme activities CYP 1A2, 2B6, 2Cl 9 and 3 A4 treated cells compared to untreated cells, the inductive potential of the test substances is determined.
  • CYP cytochrome
  • Another object of the present invention are pharmaceutical compositions containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctivae otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • Contain mold such as tablets (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings controlling the release of the compound of the invention), rapidly disintegrating tablets or films / wafers, films / lyophilisates, capsules (eg hard or soft gelatin capsules), dragees, granules, pellets, powders , Emulsions, suspensions, aerosols or solutions.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
  • absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
  • parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • Inhalation medicines including powder inhalers, nebulizers
  • nasal drops solutions, sprays
  • lingual, sublingual or buccal tablets films / wafers or capsules
  • suppositories ear or eye preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments
  • creams transdermal therapeutic systems (such as patches)
  • milk, pastes, foams, scattering powders, implants or stents for example Inhalation medicines (including powder inhalers, nebulizers), nasal drops, solutions, sprays; lingual, sublingual or buccal tablets, films / wafers or capsules, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (such as patches), Milk, pastes, foams, scattering powders, implants or stents.
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
  • excipients for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecyl sulfate, polyoxysorbitanoleate
  • binders for example polyvinylpyrrolidone
  • synthetic and natural polymers for example albumin
  • stabilizers for example, antioxidants such as ascorbic acid
  • dyes eg, inorganic pigments such as iron oxides
  • compositions containing at least one compound of the invention usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • parenteral administration per day amounts of about 0.001 to 10 mg / kg body weight to achieve effective results.
  • the amount per day is about 0.005 to 3 mg / kg of body weight.
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • the mixture of compound of the invention, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water.
  • the granules are mixed after drying with the magnesium stearate for 5 minutes.
  • This mixture is compressed with a conventional tablet press (for the tablet format see above).
  • a pressing force of 15 kN is used as a guideline for the compression.
  • a single dose of 100 mg of the compound of the invention corresponds to 10 ml of oral suspension.
  • the rhodigel is suspended in ethanol, the erf ⁇ ndungshiele connection is fed to the suspension. While stirring, the addition of water. Until the completion of the swelling of Rhodigels is stirred for about 6 h.
  • the compound of the invention is suspended in the mixture of polyethylene glycol and polysorbate with stirring. The stirring is continued until complete dissolution of the compound according to the invention.
  • the compound of the invention is sterile at a concentration below saturation solubility in a physiologically acceptable solvent (e.g., isotonic saline, glucose solution 5%, and / or PEG 400 solution.)
  • a physiologically acceptable solvent e.g., isotonic saline, glucose solution 5%, and / or PEG 400 solution.
  • the solution is sterile filtered and sterile and pyrogen-free injection wells are filled.
  • the compound of the present invention is dissolved in the water with stirring together with polyethylene glycol 400.
  • the solution is sterile-filtered (pore diameter 0.22 ⁇ m) and filled under raseptic conditions into heat-sterilized infusion bottles. These are closed with infusion stoppers and bristle caps.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de cyanopyrimidines pour préparer des agents pharmaceutiques destinés à traiter des troubles cardio-vasculaires.
EP06742947A 2005-05-27 2006-05-17 Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires Withdrawn EP1890702A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005024494A DE102005024494A1 (de) 2005-05-27 2005-05-27 Verwendung von Cyanopyrimidinen
PCT/EP2006/004639 WO2006125554A1 (fr) 2005-05-27 2006-05-17 Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires

Publications (1)

Publication Number Publication Date
EP1890702A1 true EP1890702A1 (fr) 2008-02-27

Family

ID=36888992

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06742947A Withdrawn EP1890702A1 (fr) 2005-05-27 2006-05-17 Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires

Country Status (3)

Country Link
EP (1) EP1890702A1 (fr)
DE (1) DE102005024494A1 (fr)
WO (1) WO2006125554A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1979325A1 (fr) * 2006-01-11 2008-10-15 AstraZeneca AB Dérivés de morpholinopyrimidine et leur utilisation thérapeutique
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2057129A1 (fr) * 2006-08-24 2009-05-13 AstraZeneca AB Dérivés de morpholino pyrimidine utiles dans le traitement de désordres prolifératifs
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015185499A1 (fr) * 2014-06-06 2015-12-10 H. Lundbeck A/S Inhibiteurs pde9 présentant un squelette 1-benzyl-2,5,6,8-tétrahydro-3-oxo-2,7-naphtyridine-4-carbonitrile
CN109020837A (zh) * 2018-07-27 2018-12-18 广东省石油与精细化工研究院 一种2-取代苯基-乙脒盐酸盐的制备方法
WO2024118503A1 (fr) 2022-11-28 2024-06-06 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR82004B (fr) * 1983-06-30 1984-12-12 American Home Prod
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
DE10156249A1 (de) * 2001-11-15 2003-05-28 Bayer Ag Regulation der cGMP-spezifischen Phosphodiesterase 9A
WO2004053495A1 (fr) * 2002-12-09 2004-06-24 Bayer Healthcare Ag Diagnostic et traitement de maladies associees a la phosphodiesterase 9a1(pde9a1)humaine
DE10328479A1 (de) * 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006125554A1 *

Also Published As

Publication number Publication date
WO2006125554A1 (fr) 2006-11-30
DE102005024494A1 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
JP5457476B2 (ja) 知覚力、集中力、学習力および／または記憶力の改善のために使用される６−アミノ−５−シアノ−ピリミジン−４−オン化合物
EP1902037B1 (fr) 2,4-diamino-pyrimidines comme inhibiteurs d'aurora
EP2417112B1 (fr) Diaryldihydropyrimidinones à substitution sulfonamide et sulfoximine et leur utilisation
EP1534713A1 (fr) Pyrazolopyrimidines substituees par alkyle
MX2010011591A (es) Pirimidin-5-carboxamidas sustituidas 281.
WO2004018474A1 (fr) Pyrazolopyrimidines substituees par phenyle
EP1626971B1 (fr) Pyrazolopyrimidines substituees par 6-cyclylmethyle et 6-alkylmethyle
EP0531883A1 (fr) Hétérocycles condensés à cinq chaînons, procédé pour leur fabrication et médicaments les contenant
EP1628980B1 (fr) Pyrazolopyrimidines substituees par 6-arylmethyle
EP1644339B1 (fr) 6-arylamino-5-cyano-4-pyrimidinones en tant qu'inhibiteurs de la pde9a
EP1521756A1 (fr) Imidazotriazines heterocycliquement substituees
DE102006031314A1 (de) Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
EP1890702A1 (fr) Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires
EP1467975A1 (fr) Alkyles uraciles substitues et leur utilisation
DE102005024493A1 (de) Verwendung von Pyrazolopyrimidinen
EP2298773B1 (fr) Pyrazolopyrimidines substituées par 6-cyclylméthyle et 6-alkylméthyle
US20260001860A1 (en) Methods and compositions of inhibiting dcn1-ubc12 interaction
MXPA06007982A (en) 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080917